Structure-based drug design with Kynurenine Aminotransferase-I
Human kynurenine amino transferase (KAT-1) forms the basis of a structure-based drug design study with implications for schizophrenia.
Schizophrenia is a psychosis that affects 1% of the population world wide. The molecular mechanisms that trigger schizophrenia remain elusive. Several environmental risk factors have been considered, however studies performed with twins suggest that it is a highly heritable disease. Recently attention has shifted from dopamine and serotoninergic systems (dopaminergic hyperactivity) to the additional involvement of a glutamatergic neurotransmission system in schizophrenia. One of the most widely distributed receptors at the central nervous system is the glutamatergic NMDA receptor(the NMDA glutamatergic hypofunction model). This receptor is highly sensitive to the levels of molecules such as glutamate and D-serine (the endogenous co-agonists of this receptor). Overactivity in Kynurenine Aminotransferase (KAT), which synthesizes kynurenic acid, an NMDA antagonist, may be an important link according to the glutamatergic hypofunction model of schizophrenia. To pursue large scale production of KAT-1 E.coli will be used for expression, to obtain the protein required for crystallization studies. Protein content can be estimated using a number of techniques and enzyme activity of the KAT-1 can be confirmed using kynurenine and pyruvate as substrates in HPLC assays. The methods could use expression vectors with cleavable His6 tags that provide for the use of Ni-NTA nickel-chelating resin in purification but that can easily be removed if there appears to be any interference with the crystallization process. Pure protein is required for crystallization, which allows determination of the crystallographic structure of the enzyme with inhibitors. These outcomes complement the strategies for the rational design of more potent inhibitors of KAT.
Techniques used will be HPLC, X-ray crystallography, isothermal calorimetry, molecular biology, molecular modeling, protein purification
Want to find out more?
Schizophrenia, Crystallisation, protein, complex, structure, drug design, inhibitors, rational drug design, Brain & nervous system disorders, Therapeutics & adverse drug effects, Cell biology, Genes in biology & medicine, Pharmacology & therapeutics
The opportunity ID for this research opportunity is: 215
Other opportunities with Dr W Bret Church
- Informatics and Bioinformatics-based Approaches to Protein-Ligand Interaction
- Structure-based drug design with Soluble Epoxide Hydrolase
- Understanding the Switch between Enzyme and Signaling Behaviours in Human Group IIA Secreted Phospholipase A2 by Inhibitory Intervention
- Medicinal and Pharmaceutical Chemistry — Design, Synthesis and Testing of New Anti-Bacterial Agents